18 years mitotane therapy for intractable Cushing's disease

Lancet. 1999 Sep 11;354(9182):951. doi: 10.1016/S0140-6736(05)75699-3.
No abstract available

Publication types

  • Case Reports
  • Comment
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antineoplastic Agents, Hormonal / adverse effects
  • Cushing Syndrome / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Long-Term Care
  • Mitotane / administration & dosage*
  • Mitotane / adverse effects
  • Paraneoplastic Endocrine Syndromes / drug therapy*

Substances

  • Antineoplastic Agents, Hormonal
  • Mitotane